We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
+27.09%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$655M
AUM Growth
+$111M
(+20%)
Cap. Flow
+$46.6M
Cap. Flow
% of AUM
7.12%
Top 10 Holdings %
Top 10 Hldgs %
98.53%
Holding
17
New
5
Increased
4
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$381M |
| 2 |
AstraZeneca
AZN
|
+$30.1M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$13M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$5.68M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$5.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$344M |
| 2 |
Intellia Therapeutics
NTLA
|
+$18.3M |
| 3 |
BridgeBio Pharma
BBIO
|
+$11.9M |
| 4 |
BioNTech
BNTX
|
+$11.7M |
| 5 |
Fate Therapeutics
FATE
|
+$11.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$143B
| $455M | 69.44% |
+7,697,762
| New | +$381M |
|
|
2
Intellia Therapeutics
NTLA
$1.59B
| $71.6M | 10.94% |
605,587
-146,437
| -19% | -$18.3M |
|
|
3
AstraZeneca
AZN
$262B
| $29.8M | 4.56% |
+255,954
| New | +$30.1M |
|
|
INBX
4
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $25.9M | 3.95% |
591,975
+49,389
| +9% | +$1.98M |
|
|
5
BioNTech
BNTX
$23.1B
| $23.2M | 3.55% |
90,057
-42,875
| -32% | -$11.7M |
|
|
6
Enanta Pharmaceuticals
ENTA
$400M
| $12.4M | 1.9% |
+166,190
| New | +$13M |
|
|
7
Fate Therapeutics
FATE
$324M
| $8.98M | 1.37% |
153,537
-199,713
| -57% | -$11.3M |
|
8
Keros Therapeutics
KROS
$211M
| $6.52M | 1% |
+111,500
| New | +$5.56M |
|
9
Vir Biotechnology
VIR
$1.59B
| $6.11M | 0.93% |
145,841
+100,530
| +222% | +$3.94M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.89M | 0.9% |
+161,802
| New | +$5.68M |
|
|
11
Fulcrum Therapeutics
FULC
$243M
| $5.62M | 0.86% |
317,428
+283,431
| +834% | +$5.61M |
|
12
Aclaris Therapeutics
ACRS
$793M
| $3.14M | 0.48% |
216,143
+56,750
| +36% | +$860K |
|
|
VERV
13
DELISTED
Verve Therapeutics
VERV
| $852K | 0.13% |
23,104
-4,293
| -16% | -$180K |
|
|
JBIO
14
Jade Biosciences
JBIO
$1.27B
| – | – |
-357
| Closed | -$262K |
|
|
15
BridgeBio Pharma
BBIO
$15.9B
| – | – |
-253,692
| Closed | -$11.9M |
|
16
Invivyd
IVVD
$219M
| – | – |
-86,528
| Closed | -$3.65M |
|
|
XLRN
17
DELISTED
Acceleron Pharma
XLRN
| – | – |
-2,000,000
| Closed | -$344M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q4 2021 Portfolio in Review
As of Q4 2021, Darwin Global Management held 17 positions worth $655M, up 20% from $543M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Darwin Global Management deployed $46.6M of net new capital in Q4 2021, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Pfizer: 7,697,762 shares worth $455M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Intellia Therapeutics, an estimated $18.3M trimmed.
- Darwin Global Management's largest Q4 2021 buy was Pfizer: 7,697,762 shares worth $455M.
- Darwin Global Management added most to Fulcrum Therapeutics in Q4 2021, an estimated $5.61M increase.
- Darwin Global Management's biggest Q4 2021 reduction was Intellia Therapeutics, cutting an estimated $18.3M.
- Darwin Global Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $344M.
- Darwin Global Management's ten largest holdings make up 99% of its $655M portfolio in Q4 2021.
- Darwin Global Management opened 5 new positions and closed 4 in Q4 2021.
- Darwin Global Management's portfolio value rose 20% quarter-over-quarter to $655M.
Based on Darwin Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.